CodeBreak 200 | Sotorasib | A Negligent trial that violated randomization!

(44:57)

CodeBreaK 200: sotorasib versus docetaxel in pretreated KRAS G12C-mutant NSCLC

(2:42)

CodeBreaK 200 phase III study - Additional remarks from Melissa L. Johnson during press briefing

(4:1econd)

#ESMO22 Highlights on Sotorasib in NSCLC with KRAS G12C mutation: The CodeBreaK 200 study

(2:35)

CodeBreaK 200 phase III study: Comment Prof. Dr. med. Miklos Pless | KSW Kantonsspital Winterthur

(1:27)

CodeBreak 100: sotorasib in KRAS-mutated NSCLC

(6:28)

Driver mutation lung cancer

(37:23)

ASCO 2021 Lung Recap: CodeBreak 100: Sotorasib in KRAS G12C Mutation

(5:26)

What are the latest developments in KRAS-mutant NSCLC?

(4:1econd)

KRYSTAL-1 and CodeBreak 100: targeting KRAS G12C in lung cancer

(1:26)

Sotorasib shows as a tolerable treatment option for patients with KRASG12C-mutated advanced NSCLC

(4:19)

Sotorasib outperforms docetaxel in previously treated KRAS-mutated NSCLC | Melissa Johnson

(2:59)

Sotorasib demonstrates superior PFS vs docetaxel for previously treated non-small cell lung canc...

(5:36)

Sotorasib shows superior PFS and ORR compared to docetaxel for NSCLC

(1:39)

CodeBreaK 100: detecting mechanisms of intrinsic resistance by ctDNA

(1:58)

KRAS G12C Inhibitors Versus Chemotherapy in Second Line - Targeted Therapies in Lung Cancer 2023

(3:56)

CodeBreaK 100: Patient-reported outcomes evaluating sotorasib in KRAS p.G12C mNSCLC

(2:32)

Treatment strategies for KRAS-mutant NSCLC with co-mutations

(1:37)

Overall survival in the Phase II CodeBreaK 100 trial in NSCLC

(2:24)

ASCO 2023 Expert Report on novelties in oncogene driven NSCLC by A. Curioni-Fontecedro

(4:47)